Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCLA
Dates
study started
completion around
Principal Investigator
by Gary J. Schiller, MD (ucla)
Headshot of Gary J. Schiller
Gary J. Schiller

Description

Summary

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Official Title

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Details

An open-label, Phase 1b study of R289, an IRAK 1/4 Inhibitor, to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed/refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), luspatercept, or hypomethylating agents (HMAs) for MDS.

Keywords

Low Risk Myelodysplastic Syndromes, MDS, LR MDS, Myelodysplastic Syndromes, Hematology Oncology, Hem/ Onc, Preleukemia, Syndrome, R906289 Monosodium (R289 Na)

Eligibility

Locations

  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States
  • University of California, Irvine accepting new patients
    Orange California 92868 United States

Lead Scientist at University of California Health

  • Gary J. Schiller, MD (ucla)
    Professor-in-Residence, Medicine. Authored (or co-authored) 165 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Rigel Pharmaceuticals
ID
NCT05308264
Phase
Phase 1/2 Myelodysplastic Syndrome Research Study
Study Type
Interventional
Participants
Expecting 86 study participants
Last Updated